SCHEMBL25752676

SCHEMBL25752676

Cn1cc(N)c2c(=O)n(CCOCc3ccccc3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
LTA4H P09960 1/20 0.35
GRM2 Q14416 1/20 0.35
PIM1 P11309 1/20 0.34
ALDH1A1 P00352 4/20 0.33
PKM P14618 2/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.33
GAA P10253 1/20 0.33
BRD4 O60885 1/20 0.33
TEAD3 Q99594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL27199483 0.92 MEN1 (0.34) MAOAMAOBPIM1MEN1KMT2A
SCHEMBL27199304 0.82 L3MBTL1 (0.39) MAPK14MEN1KMT2AGAATEAD3
Hydrochloric Acid SCHEMBL27199639 0.80 ALDH1A1 (0.34) ALDH1A1MEN1HPGDKMT2ATSHR
SCHEMBL25752675 0.76 PPARA (0.40) BRD4
SCHEMBL25670818 0.75 ALDH1A1 (0.33) ALDH1A1TSHR
Hydrochloric Acid SCHEMBL27199382 0.74 ALDH1A1 (0.33) ALDH1A1TSHRGAA
SCHEMBL25594902 0.73 ALDH1A1 (0.39) MAPK14MAOAMAOBLTA4HALDH1A1
SCHEMBL25670293 0.70 BRD4 (0.34) ALDH1A1SMN1; SMN2GAABRD4
Hydrochloric Acid SCHEMBL27199587 0.69 MEN1 (0.33) MEN1KMT2A
SCHEMBL16640634 0.69 NOTUM (0.48) MAPK14MAOAMAOBLTA4HGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPK14 590/4885MAOA 2304/4885MAOB 1484/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPK14 590/4885MAOA 2304/4885MAOB 1484/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAPK14 590/4885MAOA 2304/4885MAOB 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.